Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

  • Showing results for a modified search because your search retrieved no results.
1.

Differentiation and function of osteoclasts.

Miyamoto T, Suda T.

Keio J Med. 2003 Mar;52(1):1-7. Review.

2.

Osteoclast culture and resorption assays.

Bradley EW, Oursler MJ.

Methods Mol Biol. 2008;455:19-35. doi: 10.1007/978-1-59745-104-8_2.

PMID:
18463808
3.

Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.

Shinoda K, Sugiyama E, Taki H, Harada S, Mino T, Maruyama M, Kobayashi M.

Bone. 2003 Oct;33(4):711-20.

PMID:
14555277
5.

The molecular understanding of osteoclast differentiation.

Asagiri M, Takayanagi H.

Bone. 2007 Feb;40(2):251-64. Epub 2006 Nov 13. Review.

PMID:
17098490
6.

Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H.

J Immunol. 2003 Nov 15;171(10):5130-9.

7.

The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.

Kobayashi Y, Ueyama S, Arai Y, Yoshida Y, Kaneda T, Sato T, Shin K, Kumegawa M, Hakeda Y.

J Bone Miner Metab. 2004;22(4):318-28.

PMID:
15221489
8.
9.

Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.

Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.

J Cell Physiol. 2003 Jul;196(1):180-9.

PMID:
12767054
10.

Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.

Väänänen K.

Adv Drug Deliv Rev. 2005 May 25;57(7):959-71. Epub 2005 Apr 15. Review.

PMID:
15876398
12.
13.
15.

Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.

Saito K, Ohara N, Hotokezaka H, Fukumoto S, Yuasa K, Naito M, Fujiwara T, Nakayama K.

J Biol Chem. 2004 Apr 2;279(14):13555-63. Epub 2004 Jan 16.

17.

The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.

Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Löeffler M, Kodama T, Kurosawa H, Taniguchi T.

Arthritis Rheum. 2004 Mar;50(3):794-804.

18.

Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.

Uchiyama S, Yamaguchi M.

Biochem Pharmacol. 2004 Apr 1;67(7):1297-305.

PMID:
15013845
19.

NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.

Merle B, Itzstein C, Delmas PD, Chenu C.

J Cell Biochem. 2003 Oct 1;90(2):424-36.

PMID:
14505357
20.

Generation of osteoclasts in vitro, and assay of osteoclast activity.

Takahashi N, Udagawa N, Kobayashi Y, Suda T.

Methods Mol Med. 2007;135:285-301.

PMID:
17951666

Supplemental Content

Support Center